Page 3 - Diagnostics Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) and Shockwave Medical (NASDAQ:SWAV – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends. Volatility and Risk Lucid Diagnostics has a beta […]

Co-Diagnostics (NASDAQ:CODX – Get Free Report) and Biotricity (NASDAQ:BTCY – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk. Valuation and Earnings This table compares Co-Diagnostics and Biotricity’s […]

Co-Diagnostics (NASDAQ:CODX – Free Report) had its target price lowered by HC Wainwright from $2.50 to $2.00 in a research report report published on Monday, Benzinga reports. The firm currently has a neutral rating on the stock. HC Wainwright also issued estimates for Co-Diagnostics’ Q2 2024 earnings at ($0.34) EPS, Q3 2024 earnings at ($0.34) […]

Lucid Diagnostics Inc. (NASDAQ:LUCD – Free Report) – Investment analysts at Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for shares of Lucid Diagnostics in a report issued on Wednesday, May 15th. Cantor Fitzgerald analyst R. Osborn now expects that the company will earn ($1.06) per share for the year, down from their […]

Needham & Company LLC reaffirmed their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $2.50 price objective on the stock. Separately, Cantor Fitzgerald reduced their price target on shares of Lucid Diagnostics from $3.80 to $3.00 […]